GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Astellas Pharma Inc (STU:YPH) » Definitions » Asset Turnover

Astellas Pharma (STU:YPH) Asset Turnover : 0.15 (As of Dec. 2024)


View and export this data going back to . Start your Free Trial

What is Astellas Pharma Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Astellas Pharma's Revenue for the three months ended in Dec. 2024 was €3,212 Mil. Astellas Pharma's Total Assets for the quarter that ended in Dec. 2024 was €21,626 Mil. Therefore, Astellas Pharma's Asset Turnover for the quarter that ended in Dec. 2024 was 0.15.

Asset Turnover is linked to ROE % through Du Pont Formula. Astellas Pharma's annualized ROE % for the quarter that ended in Dec. 2024 was -25.64%. It is also linked to ROA % through Du Pont Formula. Astellas Pharma's annualized ROA % for the quarter that ended in Dec. 2024 was -11.22%.


Astellas Pharma Asset Turnover Historical Data

The historical data trend for Astellas Pharma's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Astellas Pharma Asset Turnover Chart

Astellas Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.63 0.52 0.56 0.61 0.50

Astellas Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.12 0.13 0.13 0.15

Competitive Comparison of Astellas Pharma's Asset Turnover

For the Drug Manufacturers - General subindustry, Astellas Pharma's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Astellas Pharma's Asset Turnover Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Astellas Pharma's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Astellas Pharma's Asset Turnover falls into.


;
;

Astellas Pharma Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Astellas Pharma's Asset Turnover for the fiscal year that ended in Mar. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Mar. 2024 )/( (Total Assets (A: Mar. 2023 )+Total Assets (A: Mar. 2024 ))/ count )
=9847.764/( (17165.3+21920.074)/ 2 )
=9847.764/19542.687
=0.50

Astellas Pharma's Asset Turnover for the quarter that ended in Dec. 2024 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2024 )/( (Total Assets (Q: Sep. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=3212.475/( (21821.534+21430.43)/ 2 )
=3212.475/21625.982
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Astellas Pharma  (STU:YPH) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Astellas Pharma's annulized ROE % for the quarter that ended in Dec. 2024 is

ROE %**(Q: Dec. 2024 )
=Net Income/Total Stockholders Equity
=-2425.4/9458.458
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-2425.4 / 12849.9)*(12849.9 / 21625.982)*(21625.982/ 9458.458)
=Net Margin %*Asset Turnover*Equity Multiplier
=-18.87 %*0.5942*2.2864
=ROA %*Equity Multiplier
=-11.22 %*2.2864
=-25.64 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Astellas Pharma's annulized ROA % for the quarter that ended in Dec. 2024 is

ROA %(Q: Dec. 2024 )
=Net Income/Total Assets
=-2425.4/21625.982
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-2425.4 / 12849.9)*(12849.9 / 21625.982)
=Net Margin %*Asset Turnover
=-18.87 %*0.5942
=-11.22 %

Note: The Net Income data used here is four times the quarterly (Dec. 2024) net income data. The Revenue data used here is four times the quarterly (Dec. 2024) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Astellas Pharma Asset Turnover Related Terms

Thank you for viewing the detailed overview of Astellas Pharma's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Astellas Pharma Business Description

Traded in Other Exchanges
Address
2-5-1, Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty global pharmaceutical company. The company focuses on accelerating the discovery, development and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. The company operates its business in approximately 70 countries around the world. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.

Astellas Pharma Headlines

No Headlines